Qinhan Hutong, a Chinese education provider that offers an art and culture curriculum, has raised RMB150 million ($21 million) in Series B funding from Mingde Chuancheng, a Shanghai-based education and consulting company.
The founders of Hong Kong-listed Li & Fung have teamed up with PE-owned warehouse operator GLP on a take-private offer that values their company at HK$10.7 billion ($1.37 billion).
Sequoia Capital China has invested of RMB1.2 billion ($171 million) in Chinese dairy products manufacturer Junlebao, becoming the largest institutional investor with a 15.26% stake.
Unable to achieve the cost-effectiveness of America's driverless grocery delivery services in China, Neolix refocused on transporting meals. Investor Yunqi Partners believes simple solutions mean quicker commercialization
Vision Plus Capital has completed the first closing on its third US dollar-denominated fund with $400 million in commitments. The vehicle comprises separate venture and growth equity capital pools.
Chinese IT platform 51CTO switched from online media to online training five years ago and hasn't looked back. With $20 million in Series C funding, the company wants to sustain its rise
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
A recent commitment by China’s CDH Investments to Wow Tech underlines how sensual health products such as vibrators are moving from the margins to the mainstream, globally and in Asia
SIG and China Renaissance New Economy Fund have co-led a $25 million Series C round for Insgeek, a Chinese insurance technology specialist.
Chinese enterprise digital solutions provider Cloudwise has raised $24 million in an extended Series D round led by Everest Venture Capital. Sequoia Capital China, WestSummit Capital, ASG and Koala Fund also participated.
Encoo Technology, a Chinese robot process automation (RPA) service provider, has raised a $30 million Series B round led by Sequoia Capital China. GSR Ventures and Future Capital re-upped, while Shenzhen Venture Capital came in as a new investor.
China-based biotech developer Harbour BioMed has closed an extended Series B round with a fresh $75 million commitment from a group of VCs. It initially raised $85 million in 2018.
Eurazeo’s Europe-China fund – a joint effort with China Investment Corporation (CIC) and BNP Paribas – will come online at the end of this month with an initial EUR400 million ($445 million) in dry powder. It is the France-based GP’s latest milestone...
Chinese celebrity management agency Mountain Top has closed a RMB180 million ($26 million) Serie B funding round provided by ByteDance Technology, operator of the Toutiao news aggregation and TikTok short video platforms.
Addor Capital and Chinese electric vehicle manufacturer Lixiang Automotive have led a RMB200 million ($28 million) in an extended Series A round for Neolix, a domestic unmanned distribution start-up.
UK-based enterprise IT services provider Ascential has acquired Yimian Data, a Chinese e-commerce analytics business backed by local VC firms ZhenFund and Legend Star.
CDH Investments has closed its sixth flagship US dollar-denominated fund with $1.5 billion in commitments. The initial target was $2.5 billion.
Shenzhen-based agricultural products distributor Wangjiahuan has raised RMB600 million ($87 million) in Series B funding led by Meituan-Dianping. Existing backer Hidden Hill Capital - a PE firm established by warehouse operator GLP - also took part.
Fenbeitong, an enterprise payment and expense management services provider based in Beijing, has raised $36 million in an extended Series B round led by Ribbit Capital, Eight Roads Ventures and Glade Brook Capital.
US private equity investor Jaguar Growth Partners has launched its first Asia fund with the acquisition of Chinese logistics operator Brilliant.
Large GPs are screening public companies more carefully so they can get comfortable with elevated valuations for public-to-private deals. At what point does discomfort become the default option?
The coronavirus outbreak has implications for PE fundraising well beyond China. Many Asia-based managers are either unable to go and see LPs or LPs are not permitted to visit them
US-based healthcare investment firm OrbiMed has launched its fourth Asian private equity fund with a view to raising $750 million.